← Back to Search

Integrase Strand Transfer Inhibitor

DOR/ISL for HIV

Phase 3
Recruiting
Research Sponsored by Merck Sharp & Dohme LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and week 96
Awards & highlights

Study Summary

This trial tests the safety, effectiveness and tolerance of a new HIV-1 treatment for people who haven't had any treatment before.

Who is the study for?
This trial is for adults with HIV-1 who haven't had any antiretroviral therapy. Women must not be pregnant, breastfeeding, or if capable of childbearing, agree to use contraception. Participants need a viral load over 500 copies/mL but can't join if they have HIV-2, recent AIDS-related infections, active hepatitis B or C with cirrhosis signs, certain cancers within the last 5 years, or conditions that might skew results.Check my eligibility
What is being tested?
The study compares two HIV treatments: DOR/ISL and BIC/FTC/TAF. It's randomized and double-blind meaning participants are put into groups by chance without knowing which treatment they get. The goal is to see if DOR/ISL works as well as BIC/FTC/TAF in reducing the virus to undetectable levels after 48 weeks.See study design
What are the potential side effects?
Possible side effects include reactions related to immune system activation such as fever and fatigue; gastrointestinal issues like nausea; potential liver problems signaled by yellowing skin or eyes; and changes in body fat distribution.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and week 96
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and week 96 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of participants discontinuing from study treatment due to an AE through Week 48
Percentage of participants experiencing ≥1 adverse event (AE) through Week 48
Percentage of participants with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/mL at Week 48
Secondary outcome measures
Change from baseline in CD4+ T-cells at Week 96
Change from baseline in body weight at Week 48
Change from baseline in body weight at Week 96
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: DOR/ISLExperimental Treatment2 Interventions
Participants take DOR/ISL and placebo to BIC/FTC/TAF once daily (qd) for 96 weeks.
Group II: BIC/FTC/TAFActive Control2 Interventions
Participants take BIC/FTC/TAF and placebo to DOR/ISL qd for 96 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DOR/ISL
2020
Completed Phase 3
~80

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor
3,906 Previous Clinical Trials
5,064,318 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,788 Previous Clinical Trials
8,065,552 Total Patients Enrolled

Media Library

BIC (Integrase Strand Transfer Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05705349 — Phase 3
HIV Research Study Groups: DOR/ISL, BIC/FTC/TAF
HIV Clinical Trial 2023: BIC Highlights & Side Effects. Trial Name: NCT05705349 — Phase 3
BIC (Integrase Strand Transfer Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05705349 — Phase 3
HIV Patient Testimony for trial: Trial Name: NCT05705349 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants still being accepted for this research?

"As indicated on clinicaltrials.gov, new participants are being welcomed into this medical trial that was first announced on March 8th 2023 and further revised 14 days later."

Answered by AI

What potential risks might patients encounter with DOR/ISL treatments?

"Our evaluation by Power granted DOR/ISL a score of 3 due to the prior clinical data validating its safety, as this is an advanced Phase 3 trial."

Answered by AI

What are the major goals of this clinical experiment?

"Per Merck Sharp & Dohme LLC, the primary outcome which will be tracked over 48 weeks is the Percentage of participants with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Secondary outcomes being evaluated include Percentage of participants experiencing any Adverse Events in a 96 week timeframe, Percentage of those discontinuing from study treatment due to an AE through Week 96 and finally the Percentage of individuals with HIV-1 RNA <50 copies/mL at Week 96 using PCR assays that detect lower than 50 copies/ml."

Answered by AI

What is the current participant pool for this research endeavor?

"Indeed, data hosted on clinicaltrials.gov affirms that this medical study is presently recruiting patients. First posted on March 8th 2023, the trial requires 500 participants from a single site for completion."

Answered by AI

Who else is applying?

What state do they live in?
Florida
What site did they apply to?
AHF The Kinder Medical Group ( Site 5672)
Regional Center for Infectious Diseases ( Site 5687)
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2

Why did patients apply to this trial?

Because I want more information about the HIV study.
PatientReceived 2+ prior treatments
~258 spots leftby Oct 2025